Health Care · Medicinal Chemicals & Botanical Products · Nasdaq · CIK 1819253 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $2.22Day +8.82%Mkt cap $81MP/E (FY) 3.0×1Y −48.8%Off 52W high −51.5%Vol (1Y) 69.5%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,043 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Price impliesUNDEMANDING · −15.4% growth |
| Short interest1.6% of sh out |
| Days to cover2.8d |
| 13F net flow (QoQ)−0.39% |
| Top-10 13F concentration82.4% |
| Next report (est.)2026-08-05 |
Fair value, confidence and the reverse-DCF grade are the MATERIALIZED daily snapshot (the same columns the screener serves), not a live model run. Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)3.0× |
| Sales (TTM)$188.2M |
| Earnings (TTM)$15.6M |
| Net margin14.1% |
| Total debt / EBITDA2.60× |
| Sales growth 3Y5.2% |
| YTD−14.6% |
| 1Y−48.8% |
| 3Y−67.4% |
| Since incept. (ann.)−22.1% |
Total return through 2026-07-30 · series begins 2022-05-27. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)69.5% |
| Ann. volatility (3Y)69.9% |
| Sharpe (1Y)−0.69 |
| Sharpe (3Y)−0.19 |
| Max drawdown (1Y)−71.4% |
| Max drawdown (3Y)−84.4% |
| Beta (3Y vs SPY)2.94 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| 325 CAPITAL LLC | 4.5M | $6M | 12.40% | +0.0% |
| Bandera Partners LLC | 2.1M | $3M | 5.63% | −9.6% |
| BlackRock, Inc. | 1.7M | $2M | 4.74% | −1.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.1M | $2M | 3.04% | new |
| ACADIAN ASSET MANAGEMENT LLC | 697,855 | $938,000 | 1.90% | +12.4% |
| STATE STREET CORP | 646,954 | $873,388 | 1.76% | +7.8% |
| GEODE CAPITAL MANAGEMENT, LLC | 615,662 | $831,320 | 1.68% | −0.7% |
| DIMENSIONAL FUND ADVISORS LP | 543,494 | $733,638 | 1.48% | −4.2% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-06 | $0.06 | −83.8% | $44.9M | −8.3% |
| 2025-12-31 | 2026-03-11 | — | — | $46.4M | −6.9% |
| 2025-09-30 | 2025-11-05 | $0.22 | −33.3% | $48.0M | −6.7% |
| 2025-06-30 | 2025-08-06 | $0.10 | — | $48.9M | −0.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-05 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 100%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
